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Abstract 
 
Context: Vitamin D deficiency has been proven to affect fertility in mammals but data in human is less 
convincing. In particular, data on in vitro fertilisation (IVF), an attractive model to draw information on 
this topic, are sparse and conflicting.  
Objective: To investigate IVF outcome in women with deficient 25-hydroxy-vitamin D [25(OH)D] serum 
levels (<20 ng/ml). 
Design: Prospective cross-sectional study. 
Setting: Infertility Unit of an academic setting.  
Patients: The main inclusion criteria were as follows: 1) indication to IVF, 2) age 18-42 years, 3) BMI 
18-25 Kg/m2, 4) adequate ovarian reserve according to Bologna criteria. Eligible women provided a serum 
sample for 25(OH)D measurement at the time of cycle preparation. Subjects were subsequently excluded 
if the cycle was cancelled or if the attempt was excessively delayed.  
Intervention: Quantitative detection of serum 25(OH)D. 
Main outcome measure: Clinical pregnancy rate. 
Results: The number of recruited women with serum 25(OH)D <20 ng/ml and ≥20 ng/ml was 154 and 
181, respectively. The clinical pregnancy rates were 20% (30/154) and 31% (56/181), respectively 
(p=0.02); the adjusted Odds Ratio for clinical pregnancy in women with vitamin D ≥20 ng/ml was 2.15 
(95%CI: 1.23-3.77). Subgroup analyses showed that the group of women with the highest serum levels 
(>30 ng/ml) had the highest chances of pregnancy. 
Conclusions: Vitamin D is an emerging factor influencing female fertility and IVF outcome. Additional 
studies are pressingly needed to confirm a causal relationship and to investigate the potential therapeutic 
benefits of vitamin D supplementation. 
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Introduction 
 
A critical role of vitamin D in the reproductive function of mammals has been known for more than three 
decades (1, 2). Mice that are deficient for 1-hydroxylase, the enzyme converting 25-hydroxy-vitamin-D 
[25(OH)D], the storage form of the vitamin, into the biologically active form 1,25-di-hydroxy-vitamin-D, 
are infertile and exhibit uterine hypoplasia and absent corpora lutea (3). Accordingly, in rodent models of 
diet-induced vitamin D deficiency, fertility is severely impaired (1). The pathogenic mechanisms 
explaining these detrimental effects are still poorly clarified but available evidence suggests that they are 
presumably multifactorial, involving the regulation of the hypothalamus-pituitary axis, ovarian 
folliculogenesis and uterine implantation (2). 
In contrast to the large body of evidence in animal models, the role of vitamin D in human reproduction 
has been less extensively investigated. The vitamin D receptor is expressed in most reproductive organs, 
including endometrium, myometrium, ovarian, cervical and breast tissues (4, 5). In vitro experiments 
suggest that, in contrast to rodents, vitamin D would be more involved in regulating embryo-implantation 
and to a lesser extent folliculogenesis (2, 6). However, in vivo data supporting a role for vitamin D in 
female fertility in general and embryo implantation in particular are not robust. In particular, evidence 
emerging from In Vitro Fertilisation (IVF), a valuable model to draw inferences on vitamin D 
insufficiency in some specific aspects of human fertility, is sparse and conflicting. Two studies evaluated 
IVF outcome based on the follicular fluid levels of 25(OH)D but results were inconsistent (7, 8). 
Moreover, four original articles investigated the association between 25(OH)D serum levels and 
pregnancy rates in IVF cycles. Rudick et al. (9) observed that the clinical pregnancy rate progressively 
decreases with declining vitamin D status in non-Hispanic whites, but not in women of Asian ethnicity. 
The same study group recently reported data on 99 recipients of egg donation of different ethnicities and 
showed a significant decline in clinical pregnancy rate with the decrease in vitamin D status (10). On the 
contrary, two recent Iranian studies failed to detect a statistically significant influence of serum 25(OH)D 
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levels on pregnancy rates (11, 12). However, both studies were performed in a population with an 
extremely low rate of subjects with sufficient serum levels of vitamin D.  
We deem it important to definitely clarify whether vitamin D deficiency negatively affects clinical 
pregnancy rate, as this may potentially open new therapeutic scenarios for women scheduled for IVF and, 
more in general, to all women with infertility. To this aim, we set up a large prospective cross-sectional 
study comparing IVF outcome in women with 25(OH)D serum levels <20 ng/ml and ≥20 ng/ml. 
 
 
Materials and Methods 
 
Between January 2012 and December 2012, all women referred to the Infertility Unit of the Fondazione 
Ca’ Granda for IVF were considered for study entry. Initial selection criteria were as follows: 1) indication 
for IVF, 2) age 18-42 years, 3) body mass index (BMI) between 18 and 25 Kg/m2 and 4) adequate ovarian 
reserve according to Bologna criteria (13). Additional exclusion criteria were a history of malignancy, 
hypertension, diabetes, multiple sclerosis, need for chronic medical treatments, autoimmune disorders and 
coronary, hepatic or renal diseases. To prevent confounders, women were subsequently excluded if they 
did not undergo fresh embryo-transfer or if time between serum measurement of 25(OH)D and embryo 
transfer exceeded an arbitrary threshold of 90 days or if they had a summer break between the 25(OH)D 
assessment and the IVF attempt. The study was approved by the local Ethical Committee and all recruited 
patients gave specific written informed consent. 
All patients selected for IVF in our Unit underwent a clinical assessment and a baseline transvaginal 
ultrasound prior to initiation of controlled ovarian hyperstimulation (COH). Eligible women accepting to 
participate provided a serum sample for 25(OH)D measurement at this time and were managed according 
to a standardised clinical protocol as reported elsewhere (14). In the case of hyper or hypo-response, the 
cycle could be cancelled before ovum pick up. Cycles could be also cancelled if the number of retrieved 
oocytes exceeded 15, in the presence of symptoms and signs suggestive of Ovarian Hyperstimulation 
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Syndrome or if serum progesterone exceeded 1,500 pg/ml at the time of human Chorionic Gonadotropin 
(hCG) administration. Serum hCG assessment to detect pregnancy was performed at +14/+16 days after 
hCG administration. If positive, women underwent a transvaginal sonography three weeks later. Clinical 
pregnancy was defined as the presence of at least one intrauterine gestational sac with viable foetus. The 
implantation rate was calculated as the number of viable embryos divided by the number of transferred 
embryos.  
The quantitative detection of total 25(OH)D levels was performed using a commercially available kit 
based on a chemiluminescence technology (DiaSorin, Stillwater, USA). The intra and inter-assay 
coefficients of variations were 10% and 15%, respectively. The physicians and biologists engaged in the 
cycle management were blinded to the results of the 25(OH)D assessment. 
Statistically significant differences were determined using Fisher’s-Exact test, Chi-Square test, Student’s 
t-test or the Wilcoxon test, as appropriate. According to WHO recommendations, women were separated 
into two different groups: 25(OH)D <20 ng/ml and ≥20 ng/ml (15). The primary outcome was the clinical 
pregnancy rate per embryo transfer. A binomial logistic regression model was used to adjust for variables 
known to be associated with pregnancy rate or 25(OH)D concentration and for those that were found to 
differ (p<0.10) between the two groups. The sample size was calculated based on an expected clinical 
pregnancy rate per embryo-transfer in patients with 25(OH)D ≥20 ng/ml of 30% and stating as clinically 
relevant a 50% relative reduction in women with deficient 25(OH)D. Setting type I and II errors to 0.05 
and 0.10, the calculated number of women to be recruited was at least 120 per study group. Based on 
preliminary evidence in our population documenting deficient 25(OH)D peripheral levels in about 50% of 
women (16) and based on the main characteristics and cycle outcome of our population (17), we planned a 
one year recruitment period. 
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Results 
 
Overall, 803 women were initially considered for enrolment. Three hundred and twenty-three of them 
were excluded for the following reasons: inclusion criteria not fulfilled (n=189), missing 25(OH)D results 
(n=10) and unsuitable time frame between 25(OH)D measurement and IVF cycle (n=124). Four hundred 
and eighty eligible women initiated the cycle. The number of women with 25(OH)D serum levels <20 
ng/ml and ≥20 ng/ml was 222 (46%) and 258 (54%), respectively. The number of women who did not 
perform fresh embryo-transfer in the two study groups was 68 (31%) and 77 (30%), respectively (p=0.92), 
leaving 154 and 181 women, respectively, for data analysis. 
The baseline clinical characteristics of the two study groups are shown in Table 1. A statistically 
significant difference emerged for ethnicity, BMI and duration of infertility. Ovarian responsiveness, 
oocyte competence, embryo development and number of embryos transferred were similar between 
groups, but women with sufficient 25(OH)D had a higher chance of obtaining top quality embryos; 
therefore, the frequency of embryo transfer at the blastocyst stage was higher (Table 2). Women with 
25(OH)D ≥20 ng/ml had a higher clinical pregnancy rate compared to those with deficient 25(OH)D 
levels. The crude odds ratio (OR) was 1.85 (95%CI: 1.11-3.08) (p=0.02). The OR adjusted for age, 
ethnicity, BMI, parity, duration of infertility, number of retrieved oocytes, number of transferred embryos 
and study period was 2.15 (95%CI: 1.23-3.77) (p=0.007). A similar figure was observed when considering 
the implantation rate; the crude OR of implantation in women with 25(OH)D ≥20 ng/ml was 1.83 (95%CI: 
1.19-2.83, p=0.006). The OR adjusted for the above mentioned variables and for the presence of at least 
one top quality embryo was 1.91 (95%CI: 1.20-3.05, p=0.006). 
Data analysis was repeated by dividing women into three rather than two categories according to serum 
25(OH)D levels: namely deficient (<20 ng/ml), insufficient (21-29 ng/ml) and sufficient (≥30 ng/ml) 
levels (18). The results are shown in Supplemental Tables 1 and 2. Of note, chances of implantation and 
pregnancy were observed to increase in accordance with the rise in categorized level of 25(OH)D. Crude 
and adjusted ORs for clinical pregnancy in women with 25(OH)D levels exceeding 30 ng/ml were 1.9 
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(95% CI 1.0-3.3; p=0.04) and 2.1 (95%CI: 1.1-4.0; p=0.03), respectively. Regarding implantation rate, the 
crude and adjusted ORs were 2.0 (95%CI: 1.2-3.2; p=0.006) and 2.2 (95%CI: 1.3-3.8; p=0.004), 
respectively. 
 
 
Discussion 
 
Based on this cross-sectional study, the clinical pregnancy rate and the implantation rate are significantly 
lower in women with vitamin D deficiency. Our results are mainly in line with those observed in the two 
studies from Rudick and co-workers (9, 10). They contrast with those from the two Iranian studies (11, 
12), but the latter two contributions were exposed to a significant risk of type II error given the extremely 
low proportion of women with sufficient vitamin D levels (11, 12). Overall, we believe that it can be 
concluded that vitamin D insufficiency negatively affects clinical pregnancy rate in women undergoing 
IVF. This effect appears to be mediated at both the ovarian and endometrial level. Indeed, despite a 
similar responsiveness to COH, the number of top quality embryos and, as a consequence, the rate of 
women reaching the stage of blastocyst transfer is higher in women with serum 25(OH)D ≥20 ng/ml. 
Moreover, the chances of embryo implantation are also enhanced. The effect of vitamin D at uterine level 
may be exerted either via the regulation of target genes such as HoxA10 or through the effects of the 
hormone on the local immune responses thought to be critical for the development of a normal pregnancy 
(6). Noteworthy, in our supplemental data analysis the best IVF outcome was observed in women with 
serum 25(OH)D ≥30 ng/ml, i.e. those with 25(OH)D sufficiency based on the most recent 
recommendations (18). 
Some limitations of our study should be recognised. Firstly, albeit statistically significant, the 95%CI of 
the ORs are ample and further evidence is thus required to obtain a more precise estimation of the 
magnitude of the association. In this regard, it has to be pointed out that our study represents the largest 
available contribution on this topic.  
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Secondly, a causal relationship between low 25(OH)D and reduced pregnancy rate can be claimed but not 
proven. It also cannot be excluded that the two conditions are only associated. The large body of evidence 
available in animal models and data from in vitro studies in women strongly favour a causal relationship 
(2), but evidence from RCTs is required to definitely support a role for vitamin D in influencing the 
chances of pregnancy. The availability of such studies would potentially markedly influence clinical 
practice considering in particular that vitamin D supplementation is a simple and cheap intervention and  
is free of relevant side effects. Also, of particular note, there is growing and consistent evidence that 
vitamin D supplementation may improve birth outcome and prevent some relevant obstetrics 
complications such as preeclampsia or gestational diabetes (19, 20).  
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Table 1.  Baseline characteristics of selected women according to vitamin D status. 
 
    
Characteristics 
Vitamin D <20 
ng/ml 
Vitamin D ≥20 
ng/ml 
p 
n=154 n=181 
    Age (years) 37.0 ± 4.3 36.8 ± 3.8 0.71 
Race 
  
0.04 
Caucasian 140 (91%) 176 (97%) 0.02 
Hispanic white  10 (6%) 1 (1%) 0.003 
Other 4 (3%) 4 (2%) 1.00 
BMI (Kg/m2) 21.1 ± 2.0 20.4 ± 2.0 0.004 
Duration of infertility (years) 4.6 ± 2.5 4.0 ± 2.5 0.03 
Previous deliveries 14 (9%) 28 (16%) 0.08 
Previous gynaecologic surgery 25 (16%) 25 (14%) 0.54 
Previous IVF cycles 91 (59%) 112 (62%) 0.65 
Day 3 serum FSH (IU/ml) 7.7 ± 3.0 8.1 ± 3.1 0.23 
AMH (ng/ml) 2.3 ± 2.2 2.2 ± 2.1 0.67 
Total AFC  10.8 ± 8.5 10.6 ± 6.7 0.81 
Indication  
   Unexplained / reduced ovarian reserve 50 (32%) 44 (24%) 0.11 
Male factor 55 (36%) 67 (37%) 0.82 
Tubal Factor / endometriosis 29 (19%) 33 (18%) 0.89 
Mixed 20 (13%) 37 (20%) 0.08 
Vitamin D serum levels (ng/ml) 14.1 ± 3.8 29.1 ± 8.3 0.001 
Days between Vitamin D test and IVF cycle 36.7 ± 22.8 33.7 ± 21.3 0.22 
        
    Data is expressed as Mean ± SD or Number (Percentage) 
  AFC: Antral Follicle Count 
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Table 2.  IVF cycle characteristics according to vitamin D status. 
  
    
Characteristics 
Vitamin D <20 
ng/ml 
Vitamin D ≥20 
ng/ml p 
n=154 n=181 
    Hyperstimulation protocol 
  
0.42 
Long protocol 62 (40%) 60 (33%) 0.21 
GnRH antagonist 54 (35%) 69 (38%) 0.57 
Flare-up 39 (25%) 52 (29%) 0.543 
Total dose of FSH used (IU) 2700 ± 1221 2655 ± 1339 0.75 
Duration of treatment (days) 9.4 ± 2.1 9.4 ± 2.0 1.00 
Number of oocytes retrieved 8.1 ± 4.2 7.9 ± 4.2 0.62 
Number of oocytes used 5.5 ± 2.8 5.5 ± 2.7 0.94 
Fertilization rate (%) 75 (56-100) 80 (63-100) 0.57 
Number of embryos at cleavage stage 3.5 ± 2.1 3.8 ± 2.2 0.15 
Number of Top Quality Embryos obtained 
  
0.01 
0 76 (49%) 74 (41%) 0.13 
1-2 69 (45%) 78 (43%) 0.83 
≥ 3 9 (6%) 29 (16%) 0.003 
Embryo Transfer stage a 
  
0.17 
Cleavage stage (Day 2) 49 (32%) 53 (29%) 0.64 
Cleavage stage (Day 3) 91 (59%) 99 (55%) 0.44 
Blastocyst stage (Day 5) 14 (9%) 29 (16%) 0.07 
Number of transferred embryos b 
  
0.62 
1 39 (25%) 51 (28%) 0,62 
2 93 (60%) 110 (61%) 1.00 
3 22 (14%) 20 (11%) 0.41 
Clinical Pregnancy 30 (20%) 56 (31%) 0.02 
Implanted embryos (Implantation Rate)  37 (13%) 70 (21%) 0.006 
        
    Data is expressed as Mean ± SD or Median (Interquartile Range) or Number (Percentage) 
 Top Quality Embryo was definied as 4-cells embryo on Day 2 or 8-cells embryo on Day 3, with a relative 
degree of fragmentation <10%. 
For variables with ≥3 categories, both general and subgroup p values are reported 
 a Transfer was performed on day 2 if the number of viable embryos on day 2 was ≤ 2 and at blastocyst stage 
(day 5) if the number of good quality embryos on day 3 was ≥ 4. In the remaining situations, embryo 
transfer was performed on day 3.  
b The number of embryos to be transferred was chosen on an individual basis taking into consideration 
prognostic factors and quality of the available embryos. 
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Supplemental Table 1.  Baseline characteristics of selected women according to vitamin D status. 
 
     
Characteristics 
Vitamin D <20 
ng/ml 
Vitamin D 20-29 
ng/ml 
Vitamin D 
≥30 ng/ml p 
n= 154 n= 117 n= 64 
     Age (years) 37.0 ± 4.3 36.7 ± 3.7 37.0 ± 4.1 0.79 
Race 
   
0.15 
Caucasian 140 (91%) 114 (97%) 62 (97%) 0.07 
Hispanic white  10 (6%) 2 (2%) 2 (3%) 0.17 
Other 4 (3%) 1 (1%) 0 (0%) 0.43 
BMI (Kg/m2) 21.1 ± 2.0 20.1 ± 2.1 20.3 ± 2.2  0.003 
Duration of infertility (years) 4.6 ± 2.5 4.1 ± 2.3 4.0 ± 2.7 0.19 
Previous deliveries 14 (9%) 15 (13%) 13 (20%) 0.07 
Previous gynaecologic surgery 25 (16%) 15 (13%) 9 (14%) 0.79 
Previous IVF cycles 91 (59%) 71 (61%) 36 (56%) 0.96 
Day 3 serum FSH (IU/ml) 7.7 ± 3.0 7.9 ± 2.9  8.5 ± 3.4 0.21 
AMH (ng/ml) 2.3 ± 2.2 2.2 ± 2.2 2.2 ± 1.8 0.91 
Total AFC  10.8 ± 8.5 10.7 ± 6.1  10.6 ± 7.5 0.98 
Indication  
   
0.01 
Unexplained / reduced ovarian reserve 50 (33%) 32 (27%) 12 (19%) 0.12 
Male factor 55 (36%) 39 (33%) 28 (44%) 0.35 
Tubal Factor / endometriosis 29 (19%) 16 (14%) 17 (27%) 0.11 
Mixed 20 (13%) 30 (26%) 7 (11%) 0.01 
Vitamin D serum levels (ng/ml) 14.1 ± 3.8 24.4 ± 2.8 37.9 ± 7.9 0.001 
Days between Vitamin D test and IVF cycle 36.7 ± 22.8 34.6 ± 24.5 32.1 ± 13.4 0.36 
          
     Data is expressed as Mean ± SD or Number (Percentage) 
   AFC: Antral Follicle Count 
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Supplemental Table 2.  IVF cycle characteristics according to vitamin D 
status. 
  
     
Characteristics 
Vitamin D 
<20 ng/ml 
Vitamin D 20-
29 ng/ml 
Vitamin D 
≥30 ng/ml p 
n= 154 n= 117 n= 64 
     Hyperstimulation protocol 
   
0.29 
Long protocol 62 (40%) 43 (37%) 17 (27%) 0.16 
GnRH antagonist 54 (35%) 39 (33%) 30 (47%) 0.17 
Flare-up 39 (25%) 35 (30%) 17 (27%) 0.70 
Total dose of FSH used (IU) 2700 ± 1221 2815 ± 1265 2492 ± 1118 0.23 
Duration of treatment (days) 9.4 ± 2.1 9.6 ± 2.1  9.1 ± 2.1 0.31 
Number of oocytes retrieved 8.1 ± 4.2 7.6 ± 4.3 8.4 ± 4.0 0.46 
Number of oocytes used 5.5 ± 2.8 5.4 ± 2.8  5.8 ± 2.6 0.68 
Fertilization rate (%) 75 (56-100) 83 (67-100) 75 (57-86) 0.13 
Number of embryos at cleavage stage 3.5 ± 2.1 3.9 ± 2.3 3.8 ± 1.9 0.29 
Number of Top Quality Embryo obtained 
   
0.05 
0 76 (49%) 47 (40%) 29 (45%) 0.32 
1-2 69 (45%) 52 (44%) 24 (38%) 0.58 
≥ 3 9 (6%) 18 (16%) 11 (17%) 0.01 
Embryo Transfer stage a 
   
0,12 
Cleavage stage (Day 2) 49 (32%) 38 (33%) 15 (23%) 0,42 
Cleavage stage (Day 3) 91 (59%) 64 (55%) 35 (55%) 0,71 
Blastocyst stage (Day 5) 14 (9%) 15 (13%) 14 (22%) 0,04 
Number of transferred embryos b 
   
0.65 
1 39 (25%) 30 (26%) 21 (33%) 0,49 
2 93 (60%) 74 (63%) 36 (56%) 0.65 
3 22 (14%) 13 (11%) 7 (11%) 0.67 
Clinical Pregnancy 30 (20%) 33 (28%) 23 (36%) 0.03 
Implanted embryos (Implantation Rate)  37 (13%) 40 (18%) 30 (26%) 0.004 
          
     Data is expressed as Mean ± SD or Median (Interquartile Range) or Number (Percentage) 
 Top Quality Embryo was defined as 4-cells embryo on Day 2 or 8-cells embryo on Day 3, with a relative 
degree of fragmentation <10%   
a Transfer was performed on day 2 if the number of viable embryos on day 2 was ≤ 2 and at blastocyst 
stage (day 5) if the number of good quality embryos on day 3 was ≥ 4. In the remaining situations, 
embryo transfer was performed on day 3.  
b The number of embryos to be transferred was chosen on an individual basis taking into consideration 
prognostic factors and quality of the available embryos. 
 
